- +91 995-222-2609
- Info@utopiathx.com
Having completed successful preclinical trials, Utopia Therapeutics is advancing toward IND-enabling studies and Phase 1 clinical trials (2024–2025), in collaboration with top research institutes in India, Southeast Asia, and the US.
We aim for fast-track regulatory pathways to address urgent global needs.
This data marks a significant leap beyond current anti-obesity treatments – delivering scalable, safe, and effective outcomes that could redefine how we treat obesity and related metabolic diseases.
Repair of intestinal epithelial lining through stem cell recruitment
Growing new skin epithelial by stem cells
Repair of intestinal epithelial lining thru stem cell recruitment
Generation of oral mucosa by stem cells
Growing new skin epithelial by stem cells
New dermis
Growing new skin epithelial by stem cells
A vaccine that targets fat metabolism to prevent and treat obesity, NAFLD, and hypertriglyceridemia.
Unlike GLP-1s that suppress appetite and cause muscle loss, our vaccine reduces fat accumulation directly without affecting appetite.
Sustainable weight loss, improved triglycerides and liver health, no muscle loss, no GI side effects, and long-lasting results.
Post-preclinical, entering IND-enabling toxicoly studies with Phase 1 trials planned.
Pharma companies, CROs, academic institutions, and public health agencies.
Reach out via the Contact page or download our Pitch Deck under “Partners & Investors.”
Enjoy a FREE Consultation on your first visit! Let our expert team help you achieve a healthier, more confident smile.
